892 related articles for article (PubMed ID: 18065103)
1. Dissolution properties and characterization of halofantrine-2-hydroxypropyl-beta-cyclodextrin binary systems.
Onyeji CO; Omoruyi SI; Oladimeji FA
Pharmazie; 2007 Nov; 62(11):858-63. PubMed ID: 18065103
[TBL] [Abstract][Full Text] [Related]
2. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
3. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
Ozdemir N; Ordu S
Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin.
Sridevi S; Chauhan AS; Chalasani KB; Jain AK; Diwan PV
Pharmazie; 2003 Nov; 58(11):807-10. PubMed ID: 14664337
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
Fathy M; Sheha M
Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin.
Liu J; Qiu L; Gao J; Jin Y
Int J Pharm; 2006 Apr; 312(1-2):137-43. PubMed ID: 16459034
[TBL] [Abstract][Full Text] [Related]
8. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.
Patil AL; Pore YV; Kuchekar BS; Late SG
Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387
[TBL] [Abstract][Full Text] [Related]
9. Complexation of tanshinone IIA with 2-hydroxypropyl-beta-cyclodextrin: effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats.
Wang L; Jiang X; Xu W; Li C
Int J Pharm; 2007 Aug; 341(1-2):58-67. PubMed ID: 17482783
[TBL] [Abstract][Full Text] [Related]
10. Effect of beta-cyclodextrin and hydroxypropyl beta-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir.
Aleem O; Kuchekar B; Pore Y; Late S
J Pharm Biomed Anal; 2008 Jul; 47(3):535-40. PubMed ID: 18367363
[TBL] [Abstract][Full Text] [Related]
11. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery.
Jug M; Maestrelli F; Bragagni M; Mura P
J Pharm Biomed Anal; 2010 May; 52(1):9-18. PubMed ID: 20004541
[TBL] [Abstract][Full Text] [Related]
12. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
13. Preformulation study of the inclusion complex warfarin-beta-cyclodextrin.
Zingone G; Rubessa F
Int J Pharm; 2005 Mar; 291(1-2):3-10. PubMed ID: 15707726
[TBL] [Abstract][Full Text] [Related]
14. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
15. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-beta-cyclodextrin ternary system.
Mura P; Bettinetti GP; Cirri M; Maestrelli F; Sorrenti M; Catenacci L
Eur J Pharm Biopharm; 2005 Jan; 59(1):99-106. PubMed ID: 15567306
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of inclusion complex of norflurazon and beta-cyclodextrin to improve herbicide formulations.
Villaverde J; Morillo E; Pérez-Martínez JI; Ginés JM; Maqueda C
J Agric Food Chem; 2004 Feb; 52(4):864-9. PubMed ID: 14969543
[TBL] [Abstract][Full Text] [Related]
17. UV-vis and FTIR-ATR characterization of 9-fluorenon-2-carboxyester/(2-hydroxypropyl)-beta-cyclodextrin inclusion complex.
Stancanelli R; Ficarra R; Cannavà C; Guardo M; Calabrò ML; Ficarra P; Ottanà R; Maccari R; Crupi V; Majolino D; Venuti V
J Pharm Biomed Anal; 2008 Aug; 47(4-5):704-9. PubMed ID: 18400444
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Liu L; Zhu S
J Pharm Biomed Anal; 2006 Jan; 40(1):122-7. PubMed ID: 16095859
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis.
Yap KL; Liu X; Thenmozhiyal JC; Ho PC
Eur J Pharm Sci; 2005 May; 25(1):49-56. PubMed ID: 15854800
[TBL] [Abstract][Full Text] [Related]
20. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes.
Aggarwal S; Singh PN; Mishra B
Pharmazie; 2002 Mar; 57(3):191-3. PubMed ID: 11933849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
